期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

MITF在黑素瘤中的研究现状及进展 被引量：11

Biological and clinical research progress of MITF in melanoma
原文传递
导出
摘要 黑素瘤源于神经脊黑素细胞,是侵袭性最强的恶性肿瘤之一。小眼畸形相关转录因子(microphthalmiaassociated transcription factor,MITF)不仅是黑素细胞生长、分化及色素生成的主要调节蛋白,其对黑素细胞的恶性转化以及黑素瘤的发生、发展及转移也发挥着重要的作用。本文将针对MITF在黑素瘤中的调控功能及其相关分子通路作一综述,以期寻找黑素瘤分子治疗的作用靶点。 Melanoma arises from the melanocyte cell lineage, it is one of the most notoriously aggressive and treatment-resistant human cancers. Microphthalmia-associated transcription factor （MITF） acts as a master regulator of melanocyte＇s development, function and survival by modulating various differentiation and cell-cycle progression genes. It also plays an oncogenic role in melanoma. MITF targeting genes important in melanoma progression include promoting survival and blocking apoptosis, stimulating proliferation, and inhibiting cell cycle. This review summarized the molecular function of MITF and its related pathways, and hope it will shed light on strategies for improving therapeutic approaches for melanoma.
作者 马家芳 孔燕 郭军
机构地区 北京大学肿瘤医院暨北京市肿瘤防治研究所肾癌黑色素瘤内科
出处 《肿瘤》 CAS CSCD 北大核心 2013年第12期1130-1134,共5页 Tumor
关键词 黑素瘤 小眼畸形相关转录因子 信号转导 细胞转化 Melanoma Microphthalmia-associated transcription factor Signal transduction Celltransdifferentiation
分类号 R739.5 [医药卫生—肿瘤]
  • 相关文献

参考文献42

  • 1TACHIBANA M, TAKEDA K, NOBUKUNI Y, et al. Ectopic expression of MITF, a gene for Waardenburg syndrome type 2, converts fibroblasts to cells with melanocyte characteristics[J]. Nat Genet, 1996, 14(1 ):50-54.
  • 2VANCE K W, CARREIRA S, BROSCH G, et al. Tbx2 is overexpressed and plays an important role in maintaining proliferation and suppression of senescence in melanomas[J]. Cancer Res, 2005, 65(6):2260-2268.
  • 3CARREIRA S, GOODALL J, AKSAN I, et al. MITF cooperates with Rbl and activates p21Cip1 expression to regulate cell cycle progression[j]. Nature, 2005, 433(7027):764-769.
  • 4DU J, WiDLUND H R, HORSTMANN M A, et al. Critical role of CDK2 for melanoma growth linked to its melanocyte- specific transcriptional regulation by MITF[J]. Cancer Cell, 2004, 6(6):565-576.
  • 5CARREIRA S, GOODALL J, DENAT L, et al. MITF regulation of Dial controls melanoma proliferation and invasiveness[J]. Genes Dev, 2006, 20(24):3426-3439.
  • 6MCGILL G G, HORSTMANN M, WlDLUND H R, et al. Bcl2 regulation by the melanocyte master regulator MITFf modulates lineage survival and melanoma cell viability[J]. Cell, 2002, 109(6):707-718.
  • 7MASCARENHAS J B, LITTLEJOHN E L, WOLSKY R J, et al. PAX3 and SOXIO activate MET receptor expression in melanoma[J]. Pigment Cell Melanoma Res, 201 0, 23(2):225-237.
  • 8CHELI Y, GIULIANO S, FENOUILLE N, et al. Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells[J]. Oncogene, 2012, 31 (19):2461-2470.
  • 9BOYLE G M, WOODS S L, BONAZZI V F, et al. Melanoma cell invasiveness is regulated by miR-211 suppression of the BRN2 transcription factor[J]. Pigment Cell Melanoma Res, 2011, 24(3):525-537.
  • 10AROZARENA I, BISCHOF H, GILBY D, et al. In melanoma, beta-catenin is a suppressor of invasion[J]. Oncogene, 2011, 30(45):4531-4543.

二级参考文献18

  • 1Falkson CI, Ibrahim J, Kirkwood JM, et al. Phase m trial of da- carbazine versus dacarbazine with interferon alpha-2b versus da- carbazine with tamoxifen versus dacarbazine with interferon alpha- 2b and tamoxifen in patients with metastatic malignant melano- ma: an Eastern Cooperative Oncology Group Study [J]. J Clin Oncol, 1998, 16(5): 1743-1751.
  • 2Avril MF, Aamdal S, Grob JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase llI study[J]. J Clin Oncol, 2004, 22(6) : 1118 -1125.
  • 3Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase 11I study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma [ J ]. J Clin Oncol, 2000, 18(1) : 158 -166.
  • 4Cui C, Mao L, Chi Z, et al. A Phase 1I, randomized, double- blind, placebo-controlled muhicenter trial of endostar in patients with metastatic melanoma [ J/OL]. Mol Ther, 2013 [ 2013-02- 20 ]. http ://www. ncbi. nlm. nih. gov/pubmed/23670576.
  • 5Cheli Y, Ohanna M, Ballotti R, et al. Fifteen-year quest for Mi- crophthalmia-associated transcription factor target genes[J]. Pig-ment Cell Melanoma Res, 2010, 23(1): 27-40.
  • 6Busc'a R, Berra E, Gaggioli C, et al. Hypoxia-inducible factor lot is a new target of Microphthalmia-associated transcription fac- tor(MITF) in melanoma cells[J]. J Cell Biol, 2005, 170( 1 ) : 49 - 59.
  • 7Ling Y, Yang Y, Lu N, et al. Endostar, a novel recombinant human endostatin, exerts antiangiogenic effective via blocking VEGF-indueed tyrosine phosphorylation of KDR/Flk-1 of endo- thelial cells [ J]. Biochem Biophys Res Commun, 2007, 361 (1) : 79 -84.
  • 8Garraway LA, Widlund HR, Rubin MA, et al. Integrative ge- nomic analyses identify MITF as a lineage survival oneogene am- plified in malignant melanoma [ J ]. Nature, 2005, 436 ( 7047 ) : 117 - 122.
  • 9Ugurel S, Houben R, Schrama D, et al. Microphthalmia-associ- ated transcription factor gene amplification in metastatic melano- ma is a prognostic marker for patient survival, but not a predic- tive marker for chemosensitivity and chemotherapy response [ J ]. Clin Cancer Res, 2007, 13 (21) : 6344 -6350.
  • 10Seetharamu N, Ott PA, Pavlick AC. Novel therapeutics for mela- noma [ J ]. Expert Rev Anticancer Ther, 2009, 9 (6) : 839 - 849.

共引文献5

同被引文献140

引证文献11

二级引证文献56

肿瘤
2013年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部